Computational antibody drug discovery platform

Antiverse is at the forefront of drug discovery, utilizing advanced machine learning techniques to revolutionize antibody design. Their innovative computational technology enables the rapid development of functional antibodies tailored for challenging drug targets, such as G-protein coupled receptors and ion channels. By leveraging machine learning, Antiverse can create target-specific antibody libraries, predicting sequences with a high binding probability without relying on pre-existing data. This approach significantly accelerates the process, allowing the transition from target identification to functional antibody development in just six months.

In addition to their machine learning capabilities, Antiverse boasts state-of-the-art laboratory facilities that support the preparation of unique cell lines. These facilities are equipped to express millions of desired receptors, enhancing the efficiency and effectiveness of their antibody design process. This combination of cutting-edge technology and robust laboratory infrastructure positions Antiverse as a leader in the field, driving forward the future of drug discovery through innovative solutions and rapid development timelines.

United Kingdom

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. 

Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

Antiverse

Company Details